[{"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-001", "question": "A 58-year-old man undergoes pancreaticoduodenectomy for a 2.5 cm pancreatic head adenocarcinoma. On postoperative day 3, his closed-suction drain has serous output of 25 mL/24 hours. Drain fluid amylase is 1,200 U/L (serum amylase 150 U/L). He is afebrile, hemodynamically stable, with soft abdomen and no leukocytosis. What is the most appropriate next step in management?", "options": ["Remove the drain", "Keep the drain and start octreotide", "Obtain contrast-enhanced CT of abdomen", "Keep the drain and discharge to home", "Return to operating room for exploration"], "answer": "A", "answer_index": 0, "explanation": "The 2016 ISGPS update defines a 'biochemical leak' as drain fluid amylase >3x serum on POD 1-3 with output <30 mL/day and no clinical sequelae, which can be managed by drain removal. Grade B fistula requires output >30 mL/day or clinical impact. The high amylase alone does not mandate retention if output remains low and the patient is clinically well.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer contradicts established postoperative pancreatic fistula management. Key stem clues: POD 3, drain amylase 1,200 U/L (8× serum), output 25 mL/24h, clinically stable. The vignette describes a Grade A (biochemical leak) pancreatic fistula per ISGPS criteria: drain amylase >3× serum with minimal output and no clinical impact. Main logical issue: The rationale states biochemical leak 'can be managed by drain removal,' but this contradicts standard practice. ISGPS guidelines and consensus management for Grade A fistula recommend keeping the drain in place until output decreases and amylase normalizes, NOT early removal. Premature drain removal risks converting a controlled leak into an intra-abdominal collection. The correct answer should be D (keep drain, discharge home) for a stable Grade A fistula, or B if conservative management with octreotide is preferred institutionally. Main medical accuracy issue: The teaching point directly contradicts safe postoperative management - removing a drain with persistent high amylase output (even if low volume) on POD 3 is premature and potentially harmful. Minimal fix: Change key to D and revise rationale to state Grade A fistulas require drain retention until biochemical resolution.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer contradicts established postoperative pancreatic fistula management. Key stem clues: POD 3, drain amylase 1,200 U/L (8× serum), output 25 mL/24h, clinically stable. The vignette describes a Grade A (biochemical leak) pancreatic fistula per ISGPS criteria: drain amylase >3× serum with minimal output and no clinical impact. Main logical issue: The rationale states biochemical leak 'can be managed by drain removal,' but this contradicts standard practice. ISGPS guidelines and consensus management for Grade A fistula recommend keeping the drain in place until output decreases and amylase normalizes, NOT early removal. Premature drain removal risks converting a controlled leak into an intra-abdominal collection. The correct answer should be D (keep drain, discharge home) for a stable Grade A fistula, or B if conservative management with octreotide is preferred institutionally. Main medical accuracy issue: The teaching point directly contradicts safe postoperative management - removing a drain with persistent high amylase output (even if low volume) on POD 3 is premature and potentially harmful. Minimal fix: Change key to D and revise rationale to state Grade A fistulas require drain retention until biochemical resolution.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-002", "question": "A 65-year-old man is diagnosed with high-grade T1 urothelial carcinoma of the bladder, 3 cm solitary lesion without carcinoma in situ. His EORTC risk score is 8. He is scheduled to begin intravesical BCG immunotherapy. What is the optimal evidence-based regimen?", "options": ["Induction only (6 weekly instillations)", "Induction plus 1-year maintenance", "Induction plus 3-year maintenance using Tice strain", "Induction plus 3-year maintenance using Connaught strain with first maintenance dose at 8 weeks", "Induction plus 2-year maintenance"], "answer": "D", "answer_index": 3, "explanation": "An EORTC score of 8 classifies high-risk disease mandating 3-year maintenance BCG. The Connaught strain demonstrates superior recurrence-free survival compared to Tice strain in meta-analyses. Maintenance must commence 8 weeks after induction completion. This regimen reduces recurrence by 37% compared to 1-year maintenance and is the standard of care for high-risk patients.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The stem correctly identifies high-risk non-muscle invasive bladder cancer (NMIBC) with EORTC score 8, appropriately indicating need for BCG with maintenance. Key discriminating findings: high-grade T1, 3cm lesion, EORTC score 8 (high-risk). The core issue is that the question asks for 'optimal evidence-based regimen' but introduces strain-specific claims unsupported by consensus guidelines. While 3-year maintenance is evidence-based (EORTC 30962, SWOG trials), the assertion that Connaught strain is superior to Tice lacks robust support in major guidelines (AUA, EAU). Meta-analyses show conflicting results, and most guidelines do not recommend one strain over another. The '8-week' timing detail, while mentioned in some protocols, is not a universally defining feature of optimal regimens. Options C and D both offer 3-year maintenance (the established standard), making them equally defensible from guideline perspective. The strain preference and precise timing introduce assumptions not established in the vignette or mainstream guidelines. Medical accuracy issues: overstates strain-specific superiority without guideline consensus. Minimal fix: Remove strain-specific details; make option simply 'Induction plus 3-year maintenance' to align with established evidence (EORTC/SWOG data).\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The stem correctly identifies high-risk non-muscle invasive bladder cancer (NMIBC) with EORTC score 8, appropriately indicating need for BCG with maintenance. Key discriminating findings: high-grade T1, 3cm lesion, EORTC score 8 (high-risk). The core issue is that the question asks for 'optimal evidence-based regimen' but introduces strain-specific claims unsupported by consensus guidelines. While 3-year maintenance is evidence-based (EORTC 30962, SWOG trials), the assertion that Connaught strain is superior to Tice lacks robust support in major guidelines (AUA, EAU). Meta-analyses show conflicting results, and most guidelines do not recommend one strain over another. The '8-week' timing detail, while mentioned in some protocols, is not a universally defining feature of optimal regimens. Options C and D both offer 3-year maintenance (the established standard), making them equally defensible from guideline perspective. The strain preference and precise timing introduce assumptions not established in the vignette or mainstream guidelines. Medical accuracy issues: overstates strain-specific superiority without guideline consensus. Minimal fix: Remove strain-specific details; make option simply 'Induction plus 3-year maintenance' to align with established evidence (EORTC/SWOG data).", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-003", "question": "A 72-year-old woman with metastatic melanoma on combination ipilimumab/nivolumab develops six watery stools daily. Laboratory studies show AST 180 U/L (upper limit of normal 40), ALT 220 U/L, and normal bilirubin. Colonoscopy reveals ulcerative colitis-like changes. What is the next step in management?", "options": ["Start prednisone 1 mg/kg plus infliximab 5 mg/kg", "Start prednisone 1 mg/kg plus vedolizumab 300 mg", "Start prednisone 1 mg/kg; if no improvement in 3-5 days add vedolizumab", "Hold immunotherapy and observe", "Start mycophenolate mofetil 1 g twice daily"], "answer": "C", "answer_index": 2, "explanation": "Grade 3 immune-related colitis with concurrent grade 2 hepatitis requires high-dose steroids (1-2 mg/kg prednisone). Infliximab is contraindicated in grade ≥2 hepatitis due to hepatotoxicity risk. Vedolizumab is the preferred second-line agent for steroid-refractory colitis without hepatic toxicity, but should be added only after 3-5 days of steroid failure rather than empirically.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes a patient on dual checkpoint inhibitors (ipilimumab/nivolumab) presenting with 6 watery stools daily (grade 3 diarrhea/colitis) plus elevated transaminases (AST 180, ALT 220) indicating concurrent grade 2 hepatitis. Key discriminating findings: (1) severe colitis requiring steroids, (2) concurrent hepatitis contraindicating infliximab (known hepatotoxic), (3) colonoscopy-confirmed colitis. The keyed answer (C) correctly initiates prednisone 1 mg/kg with conditional escalation to vedolizumab if steroid-refractory at 3-5 days. Option A is incorrect because infliximab is contraindicated with grade ≥2 hepatitis. Option B adds vedolizumab empirically without allowing steroid trial, which is premature per guidelines. Option D (observation) is inappropriate for grade 3 colitis requiring immediate treatment. Option E (mycophenolate) is not standard for immune-related colitis. The item correctly reflects current management: high-dose steroids first-line, vedolizumab (not infliximab) for steroid-refractory cases when hepatitis present. Medical accuracy is strong, aligning with ASCO/NCCN guidance on immune-related adverse events. Minimal fix: None needed; item is logically sound and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a patient on dual checkpoint inhibitors (ipilimumab/nivolumab) presenting with 6 watery stools daily (grade 3 diarrhea/colitis) plus elevated transaminases (AST 180, ALT 220) indicating concurrent grade 2 hepatitis. Key discriminating findings: (1) severe colitis requiring steroids, (2) concurrent hepatitis contraindicating infliximab (known hepatotoxic), (3) colonoscopy-confirmed colitis. The keyed answer (C) correctly initiates prednisone 1 mg/kg with conditional escalation to vedolizumab if steroid-refractory at 3-5 days. Option A is incorrect because infliximab is contraindicated with grade ≥2 hepatitis. Option B adds vedolizumab empirically without allowing steroid trial, which is premature per guidelines. Option D (observation) is inappropriate for grade 3 colitis requiring immediate treatment. Option E (mycophenolate) is not standard for immune-related colitis. The item correctly reflects current management: high-dose steroids first-line, vedolizumab (not infliximab) for steroid-refractory cases when hepatitis present. Medical accuracy is strong, aligning with ASCO/NCCN guidance on immune-related adverse events. Minimal fix: None needed; item is logically sound and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-004", "question": "A 45-year-old man with necrotizing pancreatitis is now 3 weeks from disease onset. Contrast-enhanced CT demonstrates a 9-cm walled-off necrosis in the lesser sac with a mature, well-defined wall. ERCP confirms disconnected pancreatic duct syndrome. He is febrile to 38.5°C with WBC 15,000 cells/µL. What is the definitive management?", "options": ["Immediate percutaneous catheter drainage", "Endoscopic ultrasound-guided cystgastrostomy now", "Surgical cystgastrostomy with necrosectomy now", "Delay intervention until 4 weeks then proceed endoscopically", "Continue antibiotics and observe"], "answer": "C", "answer_index": 2, "explanation": "The 2020 revised Atlanta guidelines permit intervention when WON demonstrates a mature wall, eliminating the mandatory 4-week wait. Disconnected pancreatic duct syndrome is a surgical indication because endoscopic drainage alone is associated with 40% recurrence. Surgical cystgastrostomy with necrosectomy definitively addresses both the necrosis and ductal disruption, reducing recurrence to <10%.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (Miskeyed). Verdict: The keyed answer (C) is not the current best answer; B is more defensible. Key stem clues: 3-week WON with mature wall, disconnected duct syndrome, fever/leukocytosis indicating infected necrosis. The question asks for definitive management. Main logical issue: The item is miskeyed. Modern guidelines (2020 revised Atlanta, IAP/APA 2013) advocate step-up approach starting with minimally invasive techniques. Endoscopic ultrasound-guided cystgastrostomy (B) is now first-line for WON with mature wall, even with disconnected duct syndrome. While disconnected ducts may require long-term drainage, initial endoscopic approach is preferred over upfront surgery. Surgical necrosectomy (C) is reserved for endoscopic failure or specific anatomic contraindications not mentioned here. The rationale incorrectly suggests surgery is mandatory for disconnected ducts; current evidence shows endoscopic drainage with long-term transmural stent placement achieves comparable outcomes with lower morbidity. Main medical accuracy issue: The explanation misrepresents current guidelines by overstating surgical necessity for disconnected ducts and understating endoscopic efficacy. Minimal fix: Change key to B, or add contraindications to endoscopic approach (e.g., inaccessible location, extensive necrosis extending beyond lesser sac) to justify surgical preference.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: The keyed answer (C) is not the current best answer; B is more defensible. Key stem clues: 3-week WON with mature wall, disconnected duct syndrome, fever/leukocytosis indicating infected necrosis. The question asks for definitive management. Main logical issue: The item is miskeyed. Modern guidelines (2020 revised Atlanta, IAP/APA 2013) advocate step-up approach starting with minimally invasive techniques. Endoscopic ultrasound-guided cystgastrostomy (B) is now first-line for WON with mature wall, even with disconnected duct syndrome. While disconnected ducts may require long-term drainage, initial endoscopic approach is preferred over upfront surgery. Surgical necrosectomy (C) is reserved for endoscopic failure or specific anatomic contraindications not mentioned here. The rationale incorrectly suggests surgery is mandatory for disconnected ducts; current evidence shows endoscopic drainage with long-term transmural stent placement achieves comparable outcomes with lower morbidity. Main medical accuracy issue: The explanation misrepresents current guidelines by overstating surgical necessity for disconnected ducts and understating endoscopic efficacy. Minimal fix: Change key to B, or add contraindications to endoscopic approach (e.g., inaccessible location, extensive necrosis extending beyond lesser sac) to justify surgical preference.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-005", "question": "A 58-year-old kidney transplant recipient (deceased donor, 8 months post-transplant) presents with rising creatinine from 1.2 to 2.1 mg/dL. Plasma BK virus PCR is 18,000 copies/mL. Allograft biopsy shows Banff class B BK virus nephropathy. Current immunosuppression: tacrolimus 5 mg twice daily (trough 8 ng/mL), mycophenolate mofetil 1000 mg twice daily, prednisone 5 mg daily. What is the first immunosuppression modification?", "options": ["Reduce tacrolimus dose by 50%", "Reduce mycophenolate mofetil by 50%", "Discontinue tacrolimus and switch to cyclosporine", "Discontinue mycophenolate mofetil completely", "Reduce prednisone to 2.5 mg daily"], "answer": "B", "answer_index": 1, "explanation": "For BK viremia >10,000 copies/mL with Banff class B nephropathy, first-line therapy is mycophenolate dose reduction by 50% or complete discontinuation. Tacrolimus reduction is second-line if viremia persists after 2-4 weeks. This sequence preserves tacrolimus (the cornerstone immunosuppressant) while reducing the antiproliferative agent that most impairs viral clearance. Steroids should not be reduced initially.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes BK virus nephropathy (BKVaN) with viremia >10,000 copies/mL and biopsy-proven Banff class B disease in a kidney transplant recipient. Key discriminating findings: rising creatinine, plasma BK PCR 18,000 copies/mL, histologic confirmation, and current triple immunosuppression. The question asks for the FIRST immunosuppression modification. Current consensus guidelines (KDIGO, AST) recommend initial reduction or discontinuation of the antiproliferative agent (mycophenolate mofetil) as first-line therapy, preserving calcineurin inhibitor levels initially. Option B (reduce MMF by 50%) aligns with this stepwise approach. Option A (reduce tacrolimus) is second-line if viremia persists after MMF reduction. Option D (discontinue MMF completely) is more aggressive but acceptable; however, 50% reduction is the more conservative first step. Options C and E lack support in standard protocols. The keyed answer (B) is defensible as the single best first modification, though some centers might proceed directly to MMF discontinuation (D). The item is medically accurate and logically valid under standard board-exam framing where \\\"first\\\" modification implies the most conservative initial step. Minimal fix: None required; item is unambiguous.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes BK virus nephropathy (BKVaN) with viremia >10,000 copies/mL and biopsy-proven Banff class B disease in a kidney transplant recipient. Key discriminating findings: rising creatinine, plasma BK PCR 18,000 copies/mL, histologic confirmation, and current triple immunosuppression. The question asks for the FIRST immunosuppression modification. Current consensus guidelines (KDIGO, AST) recommend initial reduction or discontinuation of the antiproliferative agent (mycophenolate mofetil) as first-line therapy, preserving calcineurin inhibitor levels initially. Option B (reduce MMF by 50%) aligns with this stepwise approach. Option A (reduce tacrolimus) is second-line if viremia persists after MMF reduction. Option D (discontinue MMF completely) is more aggressive but acceptable; however, 50% reduction is the more conservative first step. Options C and E lack support in standard protocols. The keyed answer (B) is defensible as the single best first modification, though some centers might proceed directly to MMF discontinuation (D). The item is medically accurate and logically valid under standard board-exam framing where \"first\" modification implies the most conservative initial step. Minimal fix: None required; item is unambiguous.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-006", "question": "A 62-year-old man with metastatic melanoma receives axicabtagene ciloleucel. On day 7 post-infusion, he develops confusion, expressive aphasia, and asterixis. He has a low-grade fever (37.8°C) only. ICE score is 8/10. EEG demonstrates triphasic waves. Brain MRI is normal. What is the immediate management?", "options": ["Tocilizumab 8 mg/kg intravenously once", "Dexamethasone 10 mg intravenously every 6 hours", "Methylprednisolone 1 g intravenously daily", "Tocilizumab plus dexamethasone 10 mg every 6 hours", "Supportive care with scheduled haloperidol"], "answer": "B", "answer_index": 1, "explanation": "An ICE score of 8 indicates grade 2 immune effector cell-associated neurotoxicity syndrome (ICANS), which requires dexamethasone 10 mg IV q6h. Tocilizumab is indicated for cytokine release syndrome (CRS), not ICANS, and is unnecessary for grade 1 CRS. High-dose methylprednisolone is reserved for grade ≥3 ICANS. The EEG findings are characteristic but do not escalate management beyond standard ICANS algorithms.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a patient 7 days post-CAR T-cell therapy (axicabtagene ciloleucel) presenting with confusion, expressive aphasia, asterixis, and triphasic waves on EEG—classic features of immune effector cell-associated neurotoxicity syndrome (ICANS). The ICE score of 8/10 grades this as grade 2 ICANS (ICE 3–9). The low-grade fever alone without hypotension/hypoxia suggests minimal cytokine release syndrome (CRS). Key discriminating findings: ICE score 8 (grade 2), neurologic symptoms without significant systemic CRS features. Standard ICANS management per ASTCT guidelines: grade 2 requires dexamethasone 10 mg IV q6h (option B). Tocilizumab (options A, D) targets IL-6 for CRS, not ICANS, and may worsen neurotoxicity. High-dose methylprednisolone (option C) is reserved for grade ≥3 ICANS. Supportive care alone (option E) is insufficient for grade 2. The keyed answer B aligns with consensus guidelines. Medical accuracy: fully consistent with current CAR T-cell toxicity management protocols. No logical flaws; stem provides sufficient detail (ICE score, timing, symptoms) to uniquely identify grade 2 ICANS requiring corticosteroids. Minimal fix: none needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a patient 7 days post-CAR T-cell therapy (axicabtagene ciloleucel) presenting with confusion, expressive aphasia, asterixis, and triphasic waves on EEG—classic features of immune effector cell-associated neurotoxicity syndrome (ICANS). The ICE score of 8/10 grades this as grade 2 ICANS (ICE 3–9). The low-grade fever alone without hypotension/hypoxia suggests minimal cytokine release syndrome (CRS). Key discriminating findings: ICE score 8 (grade 2), neurologic symptoms without significant systemic CRS features. Standard ICANS management per ASTCT guidelines: grade 2 requires dexamethasone 10 mg IV q6h (option B). Tocilizumab (options A, D) targets IL-6 for CRS, not ICANS, and may worsen neurotoxicity. High-dose methylprednisolone (option C) is reserved for grade ≥3 ICANS. Supportive care alone (option E) is insufficient for grade 2. The keyed answer B aligns with consensus guidelines. Medical accuracy: fully consistent with current CAR T-cell toxicity management protocols. No logical flaws; stem provides sufficient detail (ICE score, timing, symptoms) to uniquely identify grade 2 ICANS requiring corticosteroids. Minimal fix: none needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]